Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First …,

ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMA; BCMA Program Clinical Updates are Planned …, ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMA; BCMA Program Clinical Updates are Planned …, Read More

Scroll to Top